Logo

Illumina Asks US Patent Office to Investigate Affymetrix IP

Oct 25, 2005

NEW YORK, Oct. 25 (GenomeWeb News) - Illumina has asked the US Patent and Trademark Office to investigate the validity of a patent owned by Affymetrix's newly integrated ParAllele BioScience unit because Illumina said its scientists had originally invented the technology, the company said today.

 

Illumina said it has asked the USPTO for an "Interference" with US Patent No. 6,858,412, which covers molecular inversion probe genotyping technology developed by ParAllele. Whomever the USPTO identifies as the "first to invent" is "ultimately awarded ownership and entitlement to the invention under USpatent law," Illumina said.

 

Though the technology was invented by Illumina's scientists "during the course of early research and development at the company," it is "not currently in use" at Illumina, the company said in a statement. As such, the company's request for interference is based on a patent application describing the invention, which Illumina said it had filed ahead of the '412 patent. 

 

"The earlier filing date is expected to establish Illumina as the 'senior party' in the Interference proceeding, placing on the '412 patent inventors the burden of proof to establish an earlier date of invention," Illumina said in the statement.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.